title: [Management of intractable cancer pain: from intrathecal morphine to cell allograft].
abstract: The durable effectiveness of intrathecal morphine administration is well established for the management of intractable cancer pain, after failure of systemic opioids, secondary to the persistence of non-reversible undesirable side effects. Many patients are referred to late in the disease course. This conservative method to control pain of malignant origin must not be reserved for last resort treatment for terminal patients. Intra-cerebro-ventricular morphine administration is a very effective and generally safe method for controlling intractable cancer pain. Because of the chronic implantation of an intra-ventricular catheter this method is somewhat invasive. Its indications remain a simple and effective alternative when the topography of nociceptive pain is diffuse or cephalic. In clinical practice, intrathecal and/or intra-cerebro-ventricular administration of opioids is limited by cost, the need for specialized maintenance and mechanical malfunctions if implantable drug delivery systems, or by the risk of bacterial contamination and ambulatory constraints when repeated daily injections via an intrathecal access port are used. To answer these limitations, cell therapy using intrathecal chromaffin cell allograft is a promising approach for the management of cancer pain refractory to traditional drug therapy and pain lesion surgery. The basic rationale and preclinical studies on experimental pain models have enabled starting prospective clinical trials. Prior to transplantation, handling and preparation of the chromaffin tissue is critical for allograft viability. The initial results of clinical trials with human chromaffin cell grafts from intractable cancer pain have reported long-lasting pain relief, in correlation with met-enkephalin release into the CSF. Convincing evidence will require controlled studies. The limitations of this innovative cell therapy and especially the lack of human adrenal gland availability point to the need for new sources of cells. Perspectives include xenogenic or engineered cell lines.
authors.affiliation: Centre Pluridisciplinaire de Prise en Charge de la Douleur Chronique Rebelle, Service de Neurochirurgie, Hôpital Rangueil, 31403 Toulouse Cedex 04, France. Ylazorth@www.cict.fr
authors.forename: Y
authors.initials: Y
authors.lastname: Lazorthes
authors.forename: B
authors.initials: B
authors.lastname: Sallerin
authors.forename: J C
authors.initials: JC
authors.lastname: Verdie
authors.forename: J C
authors.initials: JC
authors.lastname: Sol
authors.forename: H
authors.initials: H
authors.lastname: Duplan
authors.forename: J
authors.initials: J
authors.lastname: Tkaczuk
authors.forename: M
authors.initials: M
authors.lastname: Tafani
authors.forename: R
authors.initials: R
authors.lastname: Bastide
authors.forename: J C
authors.initials: JC
authors.lastname: Bes
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage*; D019439:Chromaffin Cells / Q000637:transplantation*; D002908:Chronic Disease; D006801:Humans; D007278:Injections, Spinal; D009020:Morphine / Q000008:administration & dosage*; D009369:Neoplasms / Q000150:complications*; D010148:Intractable Pain / Q000209:etiology* / Q000628:therapy*; D011446:Prospective Studies
chemical_list: D000701:Analgesics, Opioid; D009020:Morphine